Comparison
Abacavir Hypersensitivity C5768819 vs 2 Hydroxyglutarate Aciduria C5139239
Clinical comparison between Abacavir Hypersensitivity and 2 Hydroxyglutarate Aciduria for differential diagnosis and treatment planning.
Abacavir Hypersensitivity C5768819
A potentially serious immune reaction to the HIV drug abacavir. Genetic testing is required before starting treatment to identify those at risk of this reaction.
2 Hydroxyglutarate Aciduria C5139239
A metabolic disorder causing buildup of 2-hydroxyglutaric acid. It may affect the brain and nervous system. Management includes supportive therapies and monitoring for complications.
6 comparison axes
Onset
Abacavir Hypersensitivity C5768819
Variable
2 Hydroxyglutarate Aciduria C5139239
0-10
Onset patterns differ
Severity
Abacavir Hypersensitivity C5768819
severe
2 Hydroxyglutarate Aciduria C5139239
moderate
Different severity levels
Chronic
Abacavir Hypersensitivity C5768819
Acute
2 Hydroxyglutarate Aciduria C5139239
Chronic
Differing course
Communicable
Abacavir Hypersensitivity C5768819
No
2 Hydroxyglutarate Aciduria C5139239
No
Different transmission
Body System
Abacavir Hypersensitivity C5768819
immunologic
2 Hydroxyglutarate Aciduria C5139239
metabolic
Same/different system
Category
Abacavir Hypersensitivity C5768819
immunologic
2 Hydroxyglutarate Aciduria C5139239
metabolic
Different category
Bottom line
abacavir-hypersensitivity-C5768819 and 2-hydroxyglutarate-aciduria-C5139239 differ in severity, chronicity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | Abacavir Hypersensitivity C5768819 | 2 Hydroxyglutarate Aciduria C5139239 | Discriminating power |
|---|---|---|---|
| Timing | Usually begins after abacavir exposure; onset is variable. | Typically recognized in childhood, often ages 0–10. | High |
| System involvement | Immunologic reaction that may involve multiple organs. | Metabolic disorder that may affect brain and nervous system. | High |
| Course | Acute and potentially severe while exposure continues. | Chronic, generally described as moderate, with ongoing monitoring. | Moderate |
When to favor each condition
Choose Abacavir Hypersensitivity C5768819 when
Symptoms begin after starting abacavir
Drug exposure links the reaction to an immune mechanism.
High
Required pre-treatment genetic risk testing is relevant
Screening is used to identify people at higher risk before abacavir.
High
Acute multisystem illness during HIV therapy
This pattern fits a drug reaction better than a chronic metabolic disease.
Moderate
Choose 2 Hydroxyglutarate Aciduria C5139239 when
Childhood neurologic or developmental concerns
The condition may affect the brain and nervous system.
Moderate
Persistent metabolic abnormality without drug exposure
Buildup of 2-hydroxyglutaric acid suggests a metabolic disorder.
High
Need for long-term supportive care
Management is chronic and focuses on monitoring complications.
Moderate
How key tests differ
| Test | Abacavir Hypersensitivity C5768819 | 2 Hydroxyglutarate Aciduria C5139239 | Interpretation |
|---|---|---|---|
| HLA-B*5701 screening | Used before abacavir to assess hypersensitivity risk. | Not relevant to this metabolic diagnosis. | A risk test, not proof that symptoms are hypersensitivity. |
| Urine organic acids | No characteristic 2-hydroxyglutaric acid pattern is expected. | May show elevated 2-hydroxyglutaric acid; cutoff not specified here. | An abnormal result supports evaluation but is not itself a complete diagnosis. |
| Neurologic imaging or genetic testing | Not the primary means of identifying the drug reaction. | May help assess neurologic involvement or metabolic cause. | Results require specialist interpretation and clinical correlation. |
Prognosis comparison
Abacavir Hypersensitivity C5768819
- Outcome
- Potentially severe acute reaction; long-term outcome is not established here.
- Factors
- Drug exposure, recognition, and clinician-directed management.
2 Hydroxyglutarate Aciduria C5139239
- Outcome
- Chronic course with possible neurologic effects; prognosis varies.
- Factors
- Degree of neurologic involvement and response to supportive care.
Time frame: Acute for the drug reaction; ongoing for the metabolic disorder.
Etiology, severity, chronicity, and timely specialist care.
Complications comparison
| Complication | Presentation |
|---|---|
| Acute deterioration | Potentially serious reaction; exact outcomes are not established here. Acute crises are not the defining feature in the supplied data. Urgent clinician assessment is needed for severe symptoms. |
| Neurologic complications | Not described as the primary chronic neurologic disease. Brain and nervous system involvement may occur. Type and severity vary and are not fully specified. |
| Treatment-related harm | Continued abacavir exposure may worsen the reaction. Supportive therapy and monitoring are central. Medication decisions must be made by the treating clinician. |
Patient education highlights
- HighDifferent conditions
One is a drug-related immune reaction; the other is a chronic metabolic disorder.
- HighWhen to seek care
New or worsening symptoms, especially after abacavir, need prompt medical advice.
- MediumTesting limits
Abnormal tests and genetic risk results require clinician interpretation.